Literature DB >> 4052954

Natural killer cell activity during the course of disease in patients with Hodgkin's disease.

I Frydecka.   

Abstract

Natural killer (NK) activity was investigated in 61 patients with Stage III and IV Hodgkin's disease during the course of disease and in 30 healthy age- and sex-matched healthy volunteers. The mean NK activity was significantly lower (P less than 0.001) in untreated patients and in patients in the active phase of the disease during treatment, compared with controls. There was a similar mean value of NK activity in normal subjects, compared with patients in clinical remission. NK activity correlated with the response to therapy. In patients responding to treatment, NK activity was increasing, reaching normal range in remission. The patients not responding to therapy showed gradual decrease of NK activity during the course of disease. These results suggest that the study of NK function might offer a helpful tool in following the clinical course and the efficacy of therapy, as well as for monitoring cancer patients from an immunologic viewpoint.

Entities:  

Mesh:

Year:  1985        PMID: 4052954     DOI: 10.1002/1097-0142(19851215)56:12<2799::aid-cncr2820561215>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Bone marrow and peripheral blood natural killer cell activity in lymphomas. Its response to IL-2.

Authors:  L H Caldera; M Leon-Ponte; G Acquatella; N E Bianco; I Blanca
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

2.  Clinical significance of natural killing activity in patients with advanced lymphoma.

Authors:  K Ono
Journal:  J Clin Immunol       Date:  1998-03       Impact factor: 8.317

3.  Immunological abnormalities 17 years after accidental exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  A M Jennings; G Wild; J D Ward; A M Ward
Journal:  Br J Ind Med       Date:  1988-10

4.  Natural killing activity in patients with spontaneous regression of malignant lymphoma.

Authors:  K Ono; M Kikuchi; N Funai; M Matsuzaki; Y Shimamoto
Journal:  J Clin Immunol       Date:  1996-11       Impact factor: 8.317

5.  Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies.

Authors:  Lucila N Kerbauy; Nancy D Marin; Mecit Kaplan; Pinaki P Banerjee; Melissa M Berrien-Elliott; Michelle Becker-Hapak; Rafet Basar; Mark Foster; Luciana Garcia Melo; Carly C Neal; Ethan McClain; May Daher; Ana Karen Nunez Cortes; Sweta Desai; Francesca Wei Inng Lim; Mayela Carolina Mendt; Timothy Schappe; Li Li; Hila Shaim; Mayra Shanley; Emily L Ensley; Nadima Uprety; Pamela Wong; Enli Liu; Sonny O Ang; Rong Cai; Vandana Nandivada; Vakul Mohanty; Qi Miao; Yifei Shen; Natalia Baran; Natalie W Fowlkes; Ken Chen; Luis Muniz-Feliciano; Richard E Champlin; Yago L Nieto; Joachim Koch; Martin Treder; Wolfgang Fischer; Oswaldo Keith Okamoto; Elizabeth J Shpall; Todd A Fehniger; Katayoun Rezvani
Journal:  Clin Cancer Res       Date:  2021-05-13       Impact factor: 13.801

6.  Natural killer and lymphokine activated killer cell functions in Hodgkin's disease.

Authors:  N Rajaram; R J Tatake; S H Advani; S G Gangal
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

7.  Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease.

Authors:  G Pizzolo; M Chilosi; F Vinante; F Dazzi; M Lestani; G Perona; F Benedetti; G Todeschini; C Vincenzi; L Trentin
Journal:  Br J Cancer       Date:  1987-04       Impact factor: 7.640

Review 8.  Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.

Authors:  Jodi Chiu; Daniel M Ernst; Armand Keating
Journal:  Front Immunol       Date:  2018-02-14       Impact factor: 7.561

9.  Reduced frequency of cytotoxic CD56dim CD16+ NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma.

Authors:  Elena Pánisová; Anna Lünemann; Simone Bürgler; Monika Kotur; Julien Lazarovici; Alina Danu; Meike Kaulfuss; Juliane Mietz; Obinna Chijioke; Christian Münz; Pierre Busson; Christoph Berger; David Ghez; Tarik Azzi
Journal:  Cancer Immunol Immunother       Date:  2021-05-15       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.